J Korean Ophthalmol Soc.  2011 Jul;52(7):800-806. 10.3341/jkos.2011.52.7.800.

Effect of 0.1% Sodium Hyaluronate and 0.05% Cyclosporine on Tear Film Parameters after Cataract Surgery

• Choi W
• Yoon KC

• KMID: 2214704
• DOI: http://doi.org/10.3341/jkos.2011.52.7.800

Abstract

PURPOSE
To evaluate the efficacy of topical 0.1% sodium hyaluronate (HA) and 0.05% cyclosporine A (CsA) on tear film parameters after cataract surgery.
METHODS
A total of 109 eyes of 86 patients who underwent cataract surgery were divided into four groups: 74 eyes without dry eye syndrome (groups 1 and 2) and 35 eyes with dry eye syndrome (groups 3 and 4). Groups 1 (37 eyes) and 3 (17 eyes) used 0.1% HA only, while Groups 2 (37 eyes) and 4 (18 eyes) used both 0.1% HA and 0.05% CsA. Tear film break-up time (BUT), Schirmer's test, tear clearance rate (TCR) and keratoepitheliopathy were evaluated before surgery and 1 week, 1 month, 2, 3 and 6 months after surgery.
RESULTS
But, Schirmer's test and TCR recovered at postoperative 3 months in groups 1 and 3, after 2 months in group 2 and after 1 month in group 4. Keratoepitheliopathy recovered at postoperative 1 month in groups 1, 2 and 4, after 2 months in group 3.
CONCLUSIONS
The combined use of topical 0.1% HA with 0.05% CsA is helpful in restoring tear film parameters after cataract surgery especially in patients with dry eye syndrome.

Keyword

Cataract operation; Cyclosporine; Sodium hyaluronate; Tear film parameters

MeSH Terms

Cataract
Cyclosporine
Dry Eye Syndromes
Eye
Humans
Hyaluronic Acid
Sodium
Tears
Cyclosporine
Hyaluronic Acid
Sodium

Figure

• 

  Figure 1. Changes in tear film breakup time, Schirmer's test, tear clearance rate and keratoepitheliopathy after cataract surgery in the non-dry eye groups. HA = hyaluronate; CsA = cyclosporine A.* p < 0.05 compared with each group.

• 

  Figure 2. Changes in tear film breakup time, Schirmer's test, tear clearance rate and keratoepitheliopathy after cataract surgery in the dry eye groups. HA = hyaluronate; CsA = cyclosporine A.* p < 0.05 compared with each group.

Reference

References

1. The definition of classification of dry eye diseases: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:75–92.

2. Horwath-Winter J, Vidic B, Schwantzer G, Schmut O. Early changes in corneal sensation, ocular surface integrity, and tear-film function after laser-assisted subepithelial keratectomy. J Cataract Refract Surg. 2004; 30:2316–21.

3. Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007; 26(9 Suppl 1):S16–20.

4. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000; 19:644–9.

5. Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986; 31:159–69.

6. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991; 35:369–85.

7. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol. 1989; 107:1343–8.

8. Bhan AK, Fujikawa LS, Foster CS. T-cell subsets and Langerhans cells in normal and diseased conjunctiva. Am J Ophthalmol. 1982; 94:205–12.

9. Gilbard JP, Rossi SR, Azar DT, Heyda KG. Effect of punctal occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorders. CLAO J. 1989; 15:216–8.

10. Lee EH, Jang JW, Lew HM. The changes of tear osmolarity and protein after silicone punctal plug insertion in dry eye. J Korean Ophthalmol Soc. 2001; 42:1509–14.

11. Yen MT, Pflugfelder SC, Feuer WJ. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol. 2001; 131:314–23.

12. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008; 27:64–9.

13. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007; 114:76–9.

14. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007; 26:805–9.

15. Raphael M, Bellefqih S, Piette JC, et al. Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features. Histopathology. 1988; 13:191–202.

16. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000; 118:1489–96.

17. O'Brien PD, Collum LM. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep. 2004; 4:314–9.

18. Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002; 18:411–8.

19. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993; 12:315–23.

20. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000; 19:492–6.

21. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000; 107:967–74.

22. Moon JW, Lee HJ, Shin KC, et al. Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye. Korean J Ophthalmol. 2007; 21:189–94.

23. Xu KP, Yagi Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. Cornea. 1996; 15:235–9.

24. Hiroko BM. Cataract surgery in the presence of other ocular comorbidities. Steinert RF, editor. Cataract Surgery: Technique, Complication and Management. 2nd ed.Philadelphia: Saunders;2004. chap. 32.

25. Walker TD. Benzalkonium toxicity. Clin Experiment Ophthalmol. 2004; 32:657.

26. Cho YK, Kim MS. Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol. 2009; 23:65–73.

27. Donnenfeld ED, Solomon R, Roberts CW, et al. Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. J Cataract Refract Surg. 2010; 36:1095–100.